Associate Professor Ashley Mansell is an adjunct appointed Research Group Head of the Pattern Recognition Receptors (PRR) and Inflammation research group within Hudson Institute’s Centre for Innate Immunity and Infectious Diseases.

Since 2020 he also holds the position of Head of Translational Science at Adiso Therapeutics (Boston, USA), a start-up biopharmaceutical company creating novel therapies to treat inflammatory diseases.

After completing his PhD in 2002 at Trinity College Dublin, Ireland, he returned to Australia in 2002 to lead the Toll-like receptor (TLR) research group under Prof Paul Hertzog here at the Hudson Institute, where he has continued to work on the relatively new research field of PRR signal transduction and its role in inflammatory diseases. A/Prof Mansell established his own group here at Hudson Institute in 2007.

His research group is primarily interested in understanding how PRRs recognise and signal to initiate the pro-inflammatory response, with recent focus on the role of the PRR Inflammasome family and their role in inflammatory diseases. His group are also investigating TLR-induced immunometabolism and the non-canonical role of STAT3 and TBK kinases in mediating mitochondrial reprogramming and inflammation. His group have made critical discoveries on how this pathway is turned off after activation to limit inflammation and therapeutic strategies to target inflammasome-mediated disease.

He has long-standing collaborations with leading researchers in the field, both within Australia and overseas.

Associate Professor Mansell has published his research in the highest-ranking journals, including Nature, Nature Immunology, Nature Communications, PNAS, PLoS Pathogens, Journal of Hepatology and the Journal of Biological Chemistry.  His research has been acknowledged by invitations to present at numerous international and national conferences, and he is the holder of research funding within Australia (NHMRC, Cancer Council) and overseas (Association for International Cancer Research).

 

ORCID ID: 0000-0002-6540-1281

Selected publications

• Lam M, Mansell A, Tate MD (2022) Another One Fights the Dust: Targeting the NLRP3 Inflammasome for the Treatment of Silicosis. Am J Respir Cell Mol Biol, Jun;66(6):601-611. doi: 10.1165/rcmb.2021-0545TR.

• MA Balic JJ, Albargy H, Luu K, Kirby FJ, Jayasekara WSN, Mansell F, Garama … (2020) STAT3 serine phosphorylation is required for TLR4 metabolic reprogramming and IL-1β expression. Nature Communications, 11 (1), 3816.

• S Rosli, FJ Kirby, KE Lawlor, K Rainczuk, GR Drummond, A Mansell, … (2019) Repurposing drugs targeting the P2X7 receptor to limit hyperinflammation and disease during influenza virus infection. British Journal of Pharmacology, 176 (19), 3834-3844.

• JK Dowling, MD Tate, S Rosli, NM Bourke, N Bitto, MA Lauterbach, … (2019) The Single Nucleotide Polymorphism Mal-D96N Mice Provide New Insights into Functionality of Mal in TLR Immune Responses. The Journal of Immunology, 202 (8), 2384-2396.

• SM Krishnan, YH Ling, BM Huuskes, DM Ferens, N Saini, CT Chan, … (2019) Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension. Cardiovascular research, 115 (4), 776-787.

• A Pinar, JK Dowling, NJ Bitto, AAB Robertson, E Latz, CR Stewart, … (2017) PB1-F2 peptide derived from avian influenza A virus H7N9 induces inflammation via activation of the NLRP3 inflammasome. Journal of Biological Chemistry, 292 (3), 826-836.

• MD Tate, JDH Ong, JK Dowling, JL McAuley, AB Robertson, E Latz, … (2016) Reassessing the role of the NLRP3 inflammasome during pathogenic influenza A virus infection via temporal inhibition. Scientific reports, 6 (1), 1-8.